AGENDA
The program of the 13th edition of AIS2025 will be online in early December 2024.
SCHEDULE & SPEAKERS
DAY 1
Thursday, June 20th 2024
8h00
Registration and welcome coffee
8h45
Welcome Address
- Einstein Auditorium
9h00
OPENING KEYNOTE LECTURES
- Einstein Auditorium
Next generation bispecific antibodies and antibody fusion proteins for cancer immunotherapy
Christian Klein
Distinguished Scientist, is Department Head Cancer Immunotherapy Discovery 3,
Head Oncology Programs & Site Head Roche Innovation Center Zurich
Roche pRED, Switzerland
Clinical development of bispecific antibodies and ADCs: toxicity mitigation and activity optimization strategies in expanded phase I trials
Elisa Fontana
MD, PhD, Hospital Medical Director
The Sarah Cannon Research Institute in London, UK
10h00
Coffee Break at Exhibition Hall
10h30
Paving the way for the next-generation of Antibodies & New Modalities
- Einstein Auditorium
Session I
KnotBodies: creating Ion Channel Modulating Antibodies by fusing Knottins in Antibody loops
Pedro Villar
Senior Scientist
Maxion Therapeutics, UK
From Sugars to Solutions: Advancing Cancer Therapeutics with Glycobiology
Paula Videira
Co-founder and CTO
CellmAbs
Associate Professor and Group Leader
UCIBIO, NOVA School of Science and Technology, NOVA University Lisbon, Portugal
Optimizing Discovery Strategies for TCR Bispecifics
Peter Molloy
Senior Fellow, Protein Engineering
Immunocore Ltd, UK
Leveraging cutting-edge DNA technologies to build precision libraries for antibody engineering
Radha Parmar
Science & Technology Consultant, Biologics - EMA
Twist Bioscience, USA
Antibody-based Cancer Therapies : latest developments
- Barthez Auditorium
Bispecific Antibody Drug Conjugates (BsADCs): strategies and challenges
Alain Beck
Senior Director, Biologics CMC & developability
Pierre Fabre, France
Innovative cancer therapies based on first-in-class antibodies anti-GPCR drug conjugates
Aiphi Andrée Nguyen
CEO
Skymab Biotherapeutics, France
Merus Class of Bispecific ADC (ADClonicsTM) to Achieve Improved Binding Selectivity, Internalization and Tumor Cell Killing
Peter Lowe
Director Antibody Engineering
Merus, Netherlands
Comprehensive and Reliable Characterization of Antibody Therapeutics thanks to Kimialys's innovative SPR biochips
Claude Nogues
CSO & Co-founder
Kimialys, France
12h10
Lunch at Exhibition Hall
13h00
Workshop : How to analyze NGS antibody sequence data in PipeBio
- Barthez Auditorium
Simit Patel
Senior Field Applications Scientist
PipeBio, Denmark
14h00
Paving the way for the next-generation of Antibodies & New Modalities
- Einstein Auditorium
Session II
Exploiting the advances of soloMER biologics to deliver multi-functional products for autoimmune diseases and cancer
Caroline Barelle
CEO & founder
Elasmogen, UK
De novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization
Stefan Zielonka
Global Head of Antibody Discovery & Protein Engineering
Merck Healthcare KGaA
Professor of Biomolecular Immunotherapy
Technical University of Darmstadt, Germany
Avidity Engineering : a next frontier in the development of differentiating antibody therapeutics
Simone Oostindie
Director Research & Discovery
GYES, Netherlands
Targeting tumor microenvironment with human antibodies demonstrating improved developability properties
Anne Chevrel
Head of Discovery
Mabqi, France
Discovery and Development on Non-IgG based antibodies treatments
- Barthez Auditorium
Using IgE based antibodies to treat cancer
Elizabeth Hardaker
VP of Biology
Epsilogen, UK
Engineered monoclonal IgA for the treatment of cancer
Mitchell Evers
Antibody Scientist
Utrecht University, Netherlands
Streamlining Therapeutic Antibody Development with a Homogeneous Bioluminescent Immunoassay for Signaling Pathway Analysis
Hicham Zegzouti
Senior Research Scientist - Group Leader
Promega, USA
Low-volume, automation friendly protein characterization
Sandra Flores
Field Applications Scientist
Unchained Labs, Germany
15h40
Coffee Break at Exhibition Hall
16h00
Pitch Session : Innovative Approaches and New trend Technologies
- Einstein Auditorium
Session II
Assessing the immunomodulatory effects of Immune Checkpoint Antibodies using 3D cell co-culture models
Marcin Krzykawski
CEO
Real Research, Poland
Generation of nano-antibodies using extracellular vesicles for diagnostic purposes
Clara Bouyx
Post-Doc CNRS (Operations manager of the LabCom NVDIAG)
Laboratoire d'Ingénierie des Systèmes Macromoléculaires (LISM), France
APL-1030, a Novel High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation
Mathieu Cinier
CSO
Affilogic, France
A new technology for lysosomal targeted degradation of extracellular and membrane proteins: antibody engineering with mannose 6-phosphate analogues
Ilaria Basile
R&D manager
NanoMedSyn, France
Tumor associated macrophages targeting with a new specific monoclonal antibody
Mary Poupot
Researcher
Centre de Recherche en Cancérologie de Toulouse, Inserm, France
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer
Emmanuelle Liaudet-Coopman
Senior Scientist, DR2
Institut de Recherche en Cancérologie de Montpellier (IRCM)
Inserm U1194
Université Montpellier
Institut Régional du Cancer de Montpellier (ICM), France
Involvement of tumor microenvironment during targeted radionuclide therapy
Timothée David
Post-doctoral Researcher
Institut de Recherche en Cancérologie de Montpellier (IRCM)
Inserm U1194, France
Leveraging Photonic Integrated Circuit (PIC) technology to advance label-free biosensing for antibody screening and Point of Care diagnostics
Joël van der Vegt
Business Development Specialist
Delta Life Science, The Netherlands
Epitope mapping case studies by Deep Mutational Scanning
Raphael Sierocki
CEO/CSO
Deeptope, France
Workshop ENOTTA - European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases (ENOTTA): Assembling a Multidisciplinary Puzzle
- Barthez Auditorium
Olga Pitsillidou
Officer in the Pharmaceutical Care Team
Health Insurance Organization Cyprus (HIO) & University of Groningen
Azra Guzonjić
Teaching Assistant
University of Belgrade, Serbia
Ana Homšek
Teaching Assistant
University of Belgrade, Serbia
Georgios Kararigas
Professor
University of Iceland, Iceland
17h30
Round table - Enhancing Investment Understanding
- Einstein Auditorium
Maxence de Vienne
Partner
Elyan
Lorenzo Pompei
General Delegate
Angels Santé
Adrien Clavairoly
Senior Associate
AdBio Partners
18h20
Investor's Pitch - Private session
- Barthez Auditorium
19h00
Poster Presentation - Dinner Cocktail Reception at Exhibition Hall
20h30
Announcement of « BEST POSTER » by Biothérapie Innovation Occitanie
21h00
End of DAY 1
DAY 2
Friday, June 21st 2024
8h00
Welcome coffee
8h30
Efficacity and safety from preclinical to FIH trials
- Einstein Auditorium
Session I
Feasibility Assessment in Therapeutic Antibody Development: Leveraging PK/PD Modeling to Navigate Challenges and Mitigate Pitfalls
Lionel Renaud
PK/PD and Systems Pharmacology modeler
Lyo-X, Switzerland
From preclinical to clinical: PK-PD modelling of an antibody drug conjugate for therapeutic index prediction
Laurence del Frari
Pharmacokineticist, Modeling & Simulation
Pierre Fabre, France
Pharmacokinetics strategies to support First in Human studies for different biotherapeutic modalities
Antoine Deslandes Antoine Deslandes
Global Head of Pharmacokinetics for Devices & Biotherapeutics
SANOFI, France
Non-oncology diseases/next generation of immunotherapies
- Barthez Auditorium
The role of broadly neutralizing antibodies in HIV cure strategies
Ole Søgaard
Professor
Institut for Klinisk Medicin, Aarhus University, Denmark
Multimeric complexes to unlock the therapeutic potential of innate immunity
Carole Seguin-Devaux
Head of Research Unit
Luxemburg Institut of Health, Luxemburg
Antibody-based and CAR-T cell-based therapeutic approaches against SARS-CoV2 infections
Mireia Pelegrin
DR-CNRS, Head of Antibodies, Immunomodulation and Immunotherapy group
IRMB-INSERM U1183-CHU Saint Eloi, France
10h00
Coffee Break at Exhibition Hall
10h30
Efficacity and safety from preclinical to FIH trials
- Einstein Auditorium
Session II
Case study on Clinical Dose Selection for TIGIT monospecific and bispecific antibodies
Pierre Ferre
VP Preclinical Development
Compugen Ltd, Israel
From Sugars to Solutions: Advancing Cancer Therapeutics with Glycobiology
Alex Phipps
Executive Director. Head of Clinical Pharmacology and Quantitative Pharmacology (CPQP) - Oncology
AstraZeneca, UK
Next Generation Accelerated GMP Quality Control from Master Cell Banks to Drug Substance release testing
Philippe Grimm
Business Development & Marketing Director
SGS Vitrology, UK
Screening&Fluidics, a droplet microfluidics service provider for the discovery of your biological agent
Georges Gaudrialt
CEO
Screening & Fluidics, France
Novel PK Bioanalytical Approach Using a 1.5 plex Hybrid LC-MS/MS Assay for Quantification of Total Drug (ADC/ARC) and Total Ab for Support of Non-clinical and Clinical Trials
Dawn Dufield
Scientific Officer
KCAS Bio, USA
AI and Machine Learning for Antibody discovery and Optimization
- Barthez Auditorium
Computational Approaches to Antibody Optimization and Humanization
Pietro Sormanni
Group Leader, Royal Society Univ. Research Fellow
University of Cambridge, UK
Towards an Integrated Platform for Antibody Discovery
Andrew Phillips
Head of Biologics AI Platform
SANOFI, UK
Unlocking the potential of artificial intelligence in antibody discovery
Thomas Bourquard
CSO and co-founder
MabSilico, France
12h00
Lunch at Exhibition Hall
13h00
Round Table "Nourrir l'innovation : Attirer et recruter les meilleurs talents dans l'industrie du Biomédicament"
- Barthez Auditorium
14h00
Advancing new Antibodies approaches into the Clinic
- Einstein Auditorium
First-in-Class anti-ChemR23 pro-resolutive agonist mAbs triggers the Resolution of chronic Inflammation
Nicolas Poirier
CEO
Ose Immunotherapeutics, France
Next-generation bispecific T cell engagers with built-in autoregulation to prevent treatment-related adverse events in adoptive T cell immunotherapies
Vincent Muczynski
Director of Biology
NovalGen Ltd
Research Fellow
University College London - Cancer Institut, UK
From Bench to Bedside : glenzocimab journey into the clinic
Elie Toledano
Head of Scientific Affairs and Business Intelligence
Acticor Biotech, France
Accelerating drug discovery using advanced antibody development platforms
Yu-Chih Lin
PhD. Technical specialist
Sino Biological, Germany
Innovative Approaches to overcome Bioprocessing Challenges
- Barthez Auditorium
Therapeutic Protein Charge Variant Characterization with Intact Mass and Peptide Mapping Following Microgram Preparative Capillary Isoelectric Focusing Electrophoresis Fractionation
Géry Van Vyncht
Scientific Director
Quality Assistance, Belgium
Industrialization of biotechnology process with continuous DSP approach
David Balbuena
Director of Business Development
LFB Biomanufacturing, France
Smart Technologies and Smart Processes to serve Downstream Process Intensification Levels
Fabien Rousset
Principal Expert - Chromatography / DSP, BPS - Separation Technologies
SARTORIUS, France
Synthetic Biology tools to accelerate antibody development
Tatiana Konovalova
Bioinformatics R&D manager
Thermo Fisher Scientific, Germany
15h40
Closing Keynote
- Einstein Auditorium
Bispecific Antibodies against infectious diseases
Luca Varani
Structural Biology Group Leader
Institute for Research in Biomedicine, Switzerland
16h10
Announcement of AIS2025
16h30
